Invasive mould infections: A multi-disciplinary update

Medical Mycology

Volumn 47, Issue 6, 2009, Pages 571-583

  Maschmeyer, Georg ^a   Calandra, Thierry ^b   Singh, Nina ^c   Wiley, Joseph ^d   Perfect, John ^e  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d The Herman & Walter Samuelson Children's Hospital at Sinai   (United States)

^e DUKE UNIVERSITY   (United States)

Author keywords

Amphotericin B; Aspergillosis; Azoles; Echinocandins; Neutropenia; Transplantation; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BETA 1,3 GLUCAN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; LIVER ENZYME; NYSTATIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

AEROSOL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS TERREUS; AUTOIMMUNE DISEASE; CANDIDA; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY DIAGNOSIS; EMPIRICISM; EVIDENCE BASED PRACTICE; FORCED EXPIRATORY VOLUME; FUNGAL COLONIZATION; FUNGUS ISOLATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INVASIVE MOULD INFECTION; KIDNEY FAILURE; LEUKEMIA; LUNG ASPERGILLOSIS; LUNG TRANSPLANTATION; LYMPHOMA; MORTALITY; MOULD; MUCORMYCOSIS; NAUSEA; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PEDIATRICS; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SOLID TUMOR; SYSTEMIC MYCOSIS; SYSTEMIC THERAPY; TASTE DISORDER; THORAX RADIOGRAPHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ZYGOMYCETES;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; MYCOLOGICAL TYPING TECHNIQUES; MYCOSES; ORGAN TRANSPLANTATION;

ASPERGILLUS TERREUS; ZYGOMYCETES;

EID: 70849135958     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780902946559     Document Type: Review

References (124)

1. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: Epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-1601.
2. Gotway MB, Dawn SK, Caoili EM, et al. The radiologic spectrum of pulmonary Aspergillus infections. J Comput Assist Tomogr 2002; 26: 159-173.
3. Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood 2001; 97: 1604-1610.
4. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
5. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
6. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415. (Pubitemid 34851833)
7. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: Impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448-1452.
8. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23-32.
9. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33: 641-647.
10. Bowden RA. Fungal infections after marrow transplantation. In: Bowden RA, Ljungman P, Paya CV (eds). Transplant Infections. Philadelphia: Lippincott-Raven, 1998: 339-350.
11. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin Infect Dis 2006; 43: 577-584.
12. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
13. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
14. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
15. Martino R, Subirá M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-482.
16. Boland GJ, Hene RJ, Ververs C, et al. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993; 94: 306-312.
17. Schrier RD, Rice GP, Oldstone MB. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis 1986; 153: 1084-1091.
18. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753-755.
19. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-625.
20. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005; 40(Suppl. 6): S392-S400.
21. Baddley JW, Pappas PG, Smith AC, et al. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41: 5525-5529.
22. Sutton DA, Sanche SE, Revankar SG, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345.
23. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: An emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594-1600.
24. Iwen PC, Rupp ME, Langnas AN, et al. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26: 1092-1097.
25. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
26. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
27. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-746.
28. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
29. Hope WW, Denning DW. Invasive aspergillosis: Current and future challenges in diagnosis and therapy. Clin Microbiol Infect 2004; 10: 2-4.
30. Paterson DL, Singh N. Invasive aspergillosis in transplant patients. Medicine 1999; 78: 123-138.
31. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
32. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-379.
33. Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60-66.
34. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37: 3223-3228.
35. Stynen D, Goris A, Sarfati J, et al. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
36. Bretagne S, Costa J-M, Bart-Delabesse E, et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998; 26: 1407-1412.
37. Machetti M, Feasi M, Mordini N, et al. Comparison of an enzyme immunoassay and a latex aggregation system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21: 917-921.
38. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: Early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 1996; 15: 232-237.
39. Ulusakarya A, Chachaty E, Vantelon J-M, et al. Surveillance of Aspergillus galactomannan anitgenemia for invasive aspergillosis by enzyme-linked immunosorbant assay in neutropenic patients treated for haematological malignancies. Hematol J 2000; 1: 111-116.
40. Verweij PE, Stynen D, Rijs AMMM, et al. Sandwich enzymelinked immunosorbant assay compared with Pastorex latex agglutination test for diagnosing invasive aspergilloisis in immunocompromised patients. J Clin Microbiol 1995; 33: 1912-1914.
41. Miyazaki T, Kohno S, Mitsutake K, et al. Plasma (1-3)-beta- D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J Clin Microbiol 1995; 33: 3115-3118.
42. Obayashi T, Yoshida M, Mori T, et al. Plasma (1-3)-b-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
43. Obayashi T, Yoshida M, Tamura H, et al. Determination of plasma (1-3)-b-D-glucan: A new diagnosis aid to deep mycosis. J Med Vet Mycol 1992; 30: 275-280.
44. Yuasa K, Goto H, Iguchi M, et al. Evaluation of the diagnostic value of the measurement of (1-3)-b-D-glucan in patients with pulmonary aspergillosis. Respiration 1996; 63: 78-83.
45. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46: 878-885.
46. Bart-Delabesse E, Marmorat-Khuong A, Costa JM, et al. Detection of Aspergillus DNA in bronchoalveolar lavage fluid of AIDS patients by the polymerase chain reaction [letter]. Eur J Clin Microbiol Infect Dis 1997; 16: 24-25.
47. Buchheidt D, Baust C, Skladny H, et al. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: Clinical results. Clin Infect Dis 2001; 33: 428-435.
48. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individual and patients with haematological malignancies. Blood 2003; 100: 4521-4528.
49. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504-1512.
50. Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of Aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002; 185: 1203-1206.
51. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771. (Pubitemid 29114295)
52. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234. (Pubitemid 34438861)
53. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
54. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
55. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Supplements 2007; 5: 32-42.
56. Herbrecht R, Flückinger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Supplements 2007; 5: 49-59.
57. Ullmann AJ. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr Med Res Opin 2003; 19: 263-271.
58. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-1297.
59. Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med Mycol 2006; 44: S315-S318.
60. Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis 2008; 46: 1426-1433
61. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
62. Maschmeyer G, Haas A. Voriconazole: A broad spectrum triazole for the treatment of serious and invasive fungal infections. Future Microbiol 2006; 1: 365-385.
63. Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: 395-401. (Pubitemid 46765196)
64. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
65. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
66. Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003; 20: 201-206.
67. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006; 42: E61-e65.
68. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high risk, febrile, neutropenic patients: A randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-1051.
69. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation- a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
70. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-2061.
71. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
72. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035-1041.
73. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-340.
74. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-325.
75. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
76. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
77. Marr KA, Lyons CN, Ha K, et al. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 2001; 45: 52-59.
78. Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: A reappraisal. Blood 1995; 86: 2063-2072.
79. Lionakis MS, Lewis RE, Torres HA, et al. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52: 15-20.
80. Verweij PE, Mellado E, Melchers WJG. Multiple-triazoleresistant aspergillosis. N Engl J Med 2007; 356: 1481-1483.
81. Maertens J, Frére P, Lass-Flörl C, et al. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Supplements 2007; 5: 43-48.
82. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-948.
83. Cornely OA, Böhme A, Reichert D, et al. Multinational Case Registry of the Infectious DiseasesWorking Party of the German Society for Hematology and Oncology. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939-946.
84. Singh N, Husain S. Aspergillus infections after lung transplantation: Clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22: 258-266.
85. Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000; 5: 13-19.
86. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimusbased immunosuppression. J Heart Lung Transplant 2004; 23: 632-638.
87. Selby R, Ramirez CB, Singh R, et al. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 1997; 132: 304-310.
88. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-720. (Pubitemid 27407098)
89. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52.
90. Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: Where will MELD lead us? Am J Transplant 2006; 6: 2651-2659.
91. Fortún J, Martín-Dávila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065-1070.
92. Singh N. Invasive mycoses in organ transplant recipients: Controversies in prophylaxis and management. J Antimicrob Chemother 2000; 45: 749-755. (Pubitemid 30348942)
93. Singh N, Pruett TL, Houston S, et al. Invasive aspergillosis in the recipients of liver retransplantation. Liver Transpl 2006; 12: 1205-1209. (Pubitemid 44194587)
94. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221-229.
95. Cruciani M, Mengoli C, Malena M, et al. Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transpl 2006; 12: 850-858.
96. Fortún J, Martín-Davila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-819.
97. Hellinger WC, Bonatti H, Yao JD, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11: 656-662.
98. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016. (Pubitemid 44777932)
99. Singh N, Wagener MM, Cacciarelli TV, et al. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426-431.
100. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
101. Solé A, Morant P, Salavert M, et al. Aspergillus infections in lung transplant recipients: Risk factors and outcome. Clin Microbiol Infect 2005; 11: 359-365.
102. Abbasi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999; 29: 1210-1219.
103. Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: E711-e716.
104. Groll AH, Mü ller FM, Piscitelli SC, et al. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998; 210: 264-273.
105. Gladdy RA, Richardson SE, Davies HD, et al. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 1999; 5: 16-24.
106. Ringdén O, Andström EE, Remberger M, et al. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. Pediatr Transplant 1997; 1: 124-129.
107. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Invasive fungal infections in pediatric bone marrow transplant recipients: Single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999-1004.
108. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248.
109. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172.
110. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005; 18: 484-489.
111. Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18: 702-708.
112. Herbrecht R, Auvrignon A, Andrès E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001; 20: 77-82.
113. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005; 24: 167-174.
114. Beyer J, Schwartz S, Barzen G, et al. Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis. Infection 1994; 22: 143-148.
115. Reichenspurner H, Gamberg P, Nitschke M, et al. Significant reduction in the number of fungal infections after lung-, heartlung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627-628.
116. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 1999; 93: 3654-3661.
117. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of antifungal management in lung transplantation. J Heart Lung Transplant 2004; 23: 1376-1381.
118. Eisenberg RS, OatwayWH. Nebulization of amphotericin B. Am Rev Respir Dis 1971; 103: 289-292.
119. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545-548.
120. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lungtransplant recipients. Transplantation 2004; 77: 232-237.
121. Monforte V, Ussetti P, López R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28: 170-175.
122. Alexander BD, Dodds Ashley ES, Addison RM, et al. Noncomparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006; 8: 13-20.
123. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-1408.
124. Monforte V, Román A, Gavaldà J, et al. Contamination of the nebulization systems used in the prophylaxis with amphotericin B nebulized in lung transplantation. Transplant Proc 2005; 37: 4056-4058.